Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.”
In last week’s issue of The Cancer Letter, Raja Flores wrote a guest editorial explaining how he, with his expertise in thoracic surgery, took issue with a nuance in a recent Keytruda commercial.
In this week’s episode of In the Headlines, Flores spoke with Paul Goldberg, editor and publisher of T…
Fran Visco tells the story of NBCC: “Women have declared war on breast cancer”
Fran Visco, president of The National Breast Cancer Coalition, sat down with Paul Goldberg, editor and publisher of The Cancer Letter for a special armchair discussion at the NBCC Advocate Leadership Summit in 2022. They discuss the history of NBCC and breast cancer activism, including one of the o…
9/11, mRNA, musical chairs—and an assassination attempt
This week’s oncology headlines run the gamut—from a discussion on the long-term consequences of 9/11 on lung cancer incidence, to the promise—and limits—of cutting edge mRNA science, to major institutional leadership changes, and even the intersection of cancer and war.
In this episode of The Canc…
The Galleri MCD vote: What FDA asked its advisors to ignore
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of …
Anthony Letai reflects on Year One as NCI Director: “The NCI is in business”
“I don’t know of a single grant that left my desk that was not approved and funded,” NCI Director Anthony G. Letai said on this episode of The Cancer Letter Podcast.
Letai recapped his first year as NCI director in conversation with Paul Goldberg, editor and publisher of The Cancer Letter, and laid…
As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”
As the oncology community waits with bated breath for a possible FDA approval of GRAIL’s Galleri test, NCI Director Anthony Letai has a lot to say about multi-cancer detection tests—particularly Galleri.
Letai spoke at a National Comprehensive Cancer Network policy summit on screening and preventi…
The Directors: VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs
As the Galleri test is advancing toward becoming the first multi-cancer detection test to secure FDA approval, cancer care providers are coming up with strategies for using these tests responsibly.
How will cancer centers counsel patients who walk through the doors with MCD test results? Under wha…
As USPSTF falters and FDA ignores clinical benefit, “the idea that screening is always good is probably gaining traction right now”
With the pope’s lung cancer diagnosis jumpstarting conversations about lung cancer screening, and the constant buzz surrounding multi-cancer detection tests, evidence-based evaluation of screening tests is more important than ever, Paul Goldberg, editor and publisher of The Cancer Letter, and Jacqu…
ポッドキャスト検索エンジン
当社の Web サイトを使用して、人、場所、トピックごとに 3,830,558 ポッドキャストや 196,657,032 エピソードを検索できます。
I have no special talent. I am only passionately curious, and
I listen to podcasts.
‐ Albert "Llamacorn" Einstein
